Figure 2 | Scientific Reports

Figure 2

From: Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia

Figure 2

Effect of D-520 on disaggregation of α-synuclein aggregates formed by seeding: (A) Aggregates formed by incubating 1.25 mg/mL α-syn with 0.5% PFFs for a period of 30D without shaking were incubated with D-520 for a period of 15 days. The ability of D-520 to dissociate the aggregates was studied by ThT assay at 10D and 15D of incubation. Values are represented in terms of % 0D aggregated synuclein which represents the aggregates collected at 30D from seeding. (B) Viability of PC12 cells was measured by MTT assay after 24 h treatment with aggregated synuclein incubated with D-520 collected at 10D and 15D. Values were normalized to control. Data values shown are means ± SD of three independent experiments. One-way ANOVA analysis followed by Tukey’s multiple comparison post hoc test was performed, ****p < 0.0001 and **p < 0.01 compared to aggregated Syn-0D,; $$$$p ≤ 0.0001 compared to aggregated synuclein-10D and ####p ≤ 0.0001 compared to aggregated synuclein-15D.

Back to article page